Objective. Nonsevere relapses are more common than severe relapses in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), but their clinical course and treatment outcomes remain largely unexamined. We undertook this study to analyze the outcomes of patients with nonsevere relapses in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial who were treated with prednisone according to a prespecified protocol.
Granulomatosis with polyangiitis (Wegener's) (GPA) and microscopic polyangiitis (MPA) are the major forms of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Most patients with AAV achieve at least temporary disease remission with induction regimens based on cyclophosphamide (CYC), rituximab (RTX), or methotrexate (MTX) (1) (2) (3) (4) . However, subsequent disease relapses occur in more than one-half of patients during long-term followup (5-7). The majority of such relapses are not severe and do not pose immediate threats either to major organ function or to the patient's life (2, 8, 9) . Despite reports from some clinical trials that nonsevere disease relapses are 3 times more common than severe relapses (2) , the clinical course, treatment outcomes, and ultimate implications of such disease relapses remain largely unexamined. Previous prospective trials have not provided the outcomes of nonsevere relapses (1, 2, 4, 5) , have not differentiated between severe and nonsevere relapses (10, 11) , or have not considered patients with 1 or 2 recurrent nonsevere manifestations of active disease to have experienced a relapse (8, 9) . Moreover, the terminology and definitions of nonsevere relapses have varied over the past decades, further complicating the interpretation of clinical studies (12, 13) .
We examined the outcomes of patients with nonsevere relapses in the Rituximab in ANCA-Associated Vasculitis (RAVE) trial who were treated according to a uniform protocol. The protocol consisted of a glucocorticoid increase selected at the discretion of the investigator, followed by a defined taper, without a change in nonglucocorticoid immunosuppressants.
PATIENTS AND METHODS
RAVE trial. Details of the RAVE trial design was previously reported (3, 14) . ANCA enzyme-linked immunosorbent assay kits were provided by Euroimmun. The trial enrolled ANCApositive patients with GPA or MPA who had severe disease (Birmingham Vasculitis Activity Score for Wegener's Granulomatosis [BVAS/WG] of .3, or one major item) (15) . Patients were assigned to 1 of 2 treatment groups: either CYC (2 mg/kg, adjusted for renal insufficiency) for 3-6 months followed by azathioprine (AZA) (2 mg/kg) for a total of 18 months; or RTX (4 weekly infusions of 375 mg/m 2 ) followed by placebo. Both groups received the same glucocorticoid protocol, tapered to discontinuation by 6 months.
Remission was defined as a BVAS/WG of 0, and complete remission was defined as a BVAS/WG of 0 with discontinuation of glucocorticoids. The results of the trial's primary outcomes (the percentages of patients who achieved and maintained complete remission at 6 and 18 months without additional changes in therapy) have been reported (3, 16) .
Analysis of nonsevere relapses. Patients who had an increase in the BVAS/WG of #3 and the absence of major BVAS/WG items between months 1 and 18 were included in the analysis. Three patients who had BVAS/WG of 4 at relapse were also included because their relapses were considered nonsevere by their treating physicians. The disease exacerbations analyzed included "relapses" (n 5 40), defined as an increase in the BVAS/ WG following the achievement of remission, and "flares" (n 5 4), defined as an increase in the BVAS/WG before achieving remission. For the purposes of this report, we refer to both "relapses" and "flares" as relapses. Severe relapses were defined as recurrent AAV activity that would have been treated with CYC plus highdose glucocorticoids under the standard of care that existed at the time the trial began. Patients who had a change in their initially assigned treatment prior to their first nonsevere relapse (e.g., crossover to the opposite treatment arm due to a severe relapse) were excluded from the analysis in order to limit the effects of previous therapy on the outcomes of treatments that followed first nonsevere relapses.
Treatments and followup. Patients with nonsevere relapses between months 1 and 18 were treated by increasing prednisone to a dose selected at the discretion of the investigator. The new dosage was maintained for 1 month before resumption of a specified taper every 2 weeks, as follows: 60 mg/day, 40 mg/day, 30 mg/day, 20 mg/day, 15 mg/day, 10 mg/day, 7.5 mg/day, 5 mg/ day, and 2.5 mg/day. In order to study clinical events after the first nonsevere relapse, patients' outcome data were analyzed until one of the following occurred: a severe relapse, a second nonsevere relapse, a change in nonglucocorticoid immunosuppressants, withdrawal from the trial, or the common closeout date.
Statistical analysis. Binary outcomes were compared using the chi-square test or Fisher's exact test. Continuous outcomes between treatment arms were compared using the Wilcoxon rank sum test. Wald confidence intervals of 95% were calculated for differences in outcomes between treatment arms at the different time points. The data sets for these analyses are accessible through TrialShare (https:// www.itntrialshare.org), a publicly accessible web site developed by the Immune Tolerance Network.
RESULTS
Numbers of nonsevere relapses. Sixty-seven nonsevere relapses occurred in 51 patients between months 
1 (4) 3 (14) 4 ( Patient characteristics at first nonsevere relapse. Thirty-six patients (82%) were proteinase 3 (PR3)-ANCA positive and 40 (91%) had GPA (Table  1) . Twenty-eight patients (64%) had relapsing disease at study entry. Compared to the subset of patients who achieved and maintained disease remission through 18 months of followup (n 5 71), patients who experienced nonsevere relapses had significantly more frequent PR3-ANCA positivity at baseline, GPA diagnosis, and history of relapsing disease (Table 2) . Among the 44 patients with nonsevere relapses, 24 (55%) had all 3 of these characteristics as compared to 30% of the patients who maintained disease remission (P , 0.01).
Forty of 44 patients (91%) achieved remission (BVAS/WG of 0) before experiencing their first nonsevere relapse, which occurred on average 7.5 months (range 1.8-16.9 months) after study entry (7.7 months in the group receiving RTX versus 7.3 months in the group receiving CYC/AZA; P . 0.99). Sixteen of 44 patients (36%) were still receiving prednisone at the time of their first relapse (median 5.0 mg/day, range 2.5-20.0). Of the 21 patients in the group receiving CYC/AZA, 2 were receiving CYC at the time of relapse. Thirty-three patients had ANCAs measured at the first nonsevere relapse, and 32 had B cells measured. Ten patients (30%) were negative for ANCAs (30% in the group receiving RTX, 31% in the group receiving CYC/AZA) and 14 patients (44%) had undetectable B cells (45% in the group receiving RTX, 42% in the group receiving CYC/AZA). Five of 32 patients (16%) were both negative for ANCAs and had undetectable B cells at relapse.
The most common manifestations of nonsevere relapses were constitutional symptoms; ear, nose, and throat findings; ocular disease; and pulmonary involvement. Only 4 relapses (9%) were characterized by active kidney disease (hematuria in 4 patients, red blood cell casts in 1 patient). No patient had an increase in the serum creatinine level of .30%.
Treatment of first nonsevere relapse. After the first nonsevere disease relapse, patients' data were analyzed over a mean of 12.5 months (range 0.7-39.2 months) (7.8 months in the group receiving RTX versus 17.6 months in the group receiving CYC/AZA; P , 0.01) until a recurrent relapse, a change in nonglucocorticoid immunosuppressants, or the occurrence of the last study visit, whichever came first. An increase in prednisone led to remission in 35 of 44 patients (80%) (17 of 23 patients in the group receiving RTX [74%] versus 18 of 21 patients in the group receiving CYC/AZA [86%]; P 5 0.46) ( Table 3 ). The median prednisone dosage used to treat nonsevere relapses was 17.5 mg/day (range 2.5-80) (11 mg/day in the group receiving RTX, 20 mg/day in the group receiving CYC/AZA). However, disease remained in remission in only 13 patients (30%) (8 in the group receiving RTX, 5 in the group receiving CYC/AZA) until the conclusion of followup ( Figure 1 ). The remaining patients had second relapses ( Figure 2 ). Of the 13 patients whose disease remained in remission, 5 were censored at the 18-month time point because they were started on an additional immunosuppressive medication at the discretion of their treating physician (4 in the group receiving RTX added AZA, and 1 in the group receiving CYC/AZA added RTX). The dose of prednisone used to treat the first nonsevere relapse did not appear to influence patient outcomes (Table 4) . A similar percentage of patients achieved remission and maintained remission when treated with high-dose prednisone ($20 mg/day) as opposed to low-dose prednisone (,20 mg/day). Seventyseven percent of the patients with relapsing disease who were treated with high-dose prednisone achieved remission, and 23% of those patients maintained those remissions for the remainder of followup. In comparison, 82% of the patients with relapsing disease who were treated with low-dose prednisone achieved remission, and 36% maintained those remissions. A patient's likelihood of maintaining remission did not differ according to ANCA type (10 of 36 patients with PR3-ANCAs [28%] versus 3 of 8 patients with myeloperoxidase [MPO]-ANCAs [38%]; P 5 0.68). Of the 4 patients with MPA, 3 had disease that remained in remission and 1 had a severe relapse of disease.
Characteristics of second relapses following first nonsevere relapses. Of the 31 patients who were not able to achieve and maintain remission throughout the followup period, 17 experienced a second nonsevere relapse (10 in the group receiving RTX, 7 in the group receiving CYC/AZA) and 14 experienced a severe relapse (5 in the group receiving RTX, 9 in the group receiving CYC/AZA). There were no differences in baseline characteristics or organ involvement at the first relapse between patients whose second relapse was severe and those whose second relapse was nonsevere (data not shown). Furthermore, the prednisone dose used to treat the first relapse did not appear to affect the likelihood that a second relapse would be severe. Thirty-six percent of patients treated with high-dose prednisone experienced a second nonsevere relapse compared to 41% of those treated with low-dose prednisone. Forty-one percent of patients treated with high-dose prednisone experienced a severe relapse compared to 23% of those treated with low-dose prednisone. The mean time to second relapse was 9.4 months following the initial relapse (4.7 months in the group receiving RTX versus 13.7 months in the group receiving CYC/AZA; P , 0.01). Sixteen of the 31 patients (52%) were still receiving prednisone at the time of second relapse (median 7.5 mg/day, range 2. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . Of the 25 patients in whom ANCAs and B cells were measured at the time of their second relapses, ANCAs were present or increasing in 21 (84%) and B cells were detectable or reconstituted in 21 (84%). Only 1 patient had no ANCAs and undetectable B cells at the time of second relapse.
Cumulative prednisone doses and adverse events. Patients who had a nonsevere relapse had a greater mean cumulative prednisone dose over the first 18 months of the trial compared to patients who reached the primary end point (6.7 grams versus 3.8 grams; P , 0.01). Through the 18-month time point, there were no differences in adverse events between patients who experienced nonsevere relapses and those who achieved the primary end point (0.94 events per patient-year and 0.91 events per patient-year, respectively; P 5 0.08). There were 5 severe infections among the 44 patients with disease relapse and 8 among the 71 patients who reached the primary end point. Damage, as measured by the Vasculitis Damage Index (VDI) (17) , increased from trial entry to the first nonsevere relapse and again at the end of followup (mean values of 1.2, 1.6, and 2.3, respectively). However, the mean VDI increased at a similar rate for patients who reached the primary end point at 18 months (from 1.0 to 2.1) (P 5 0.99).
DISCUSSION
Despite an expansion of the options for inductionof-remission regimens in AAV over the past 2 decades, disease relapses remain a therapeutic challenge. Our report is the first in which the outcomes of patients with nonsevere relapses are described. Although 80% of patients achieved remission after an increase in their prednisone dose, 70% of those patients went on to experience a second relapse, either nonsevere or severe, within an average of 6 months. Only 13 patients (30%) were able to maintain disease-free remissions until the end of followup, and only 8 (18%) were able to do so until their last study visit. These findings identify an important subset of patients with AAV who are unable to maintain prolonged remission and, as a result, receive higher doses of glucocorticoids. Such patients are more likely to have GPA, be PR3-ANCA positive, and have relapsing disease.
Because patients with nonsevere relapses constitute an important clinical subset, our definition of nonsevere relapse should be considered in the context of terminology previously used to characterize nonsevere AAV. Carrington and Liebow first used the term "limited Wegener's granulomatosis" to describe GPA that primarily involved the lungs as opposed to the kidneys (12) . In 1992, Hoffman et al reported on the use of MTX and glucocorticoids in GPA patients with mild renal involvement, and such patients were also classified as having "limited" GPA (18) . Several other studies also used this nomenclature (4, 6, 19) . Thus, "limited" GPA has often been defined more broadly (particularly in the US) as disease activity that does not pose immediate threats either to major organ function or to the patient's life and that does not require treatment with CYC (2).
Several other terms have been used to describe nonsevere relapses. The European Vasculitis Study Group has used the terms "localized" to define disease confined to the upper or lower respiratory tract without constitutional symptoms and "early systemic" disease to define AAV without progressive end-organ damage and with creatinine concentrations of ,120 mmoles/liter (1.35 mg/dl) (13) . The "localized" and "early systemic" designations correspond approximately to the "limited" category. Finally, the term "minor relapse" has been used with widely varying definitions in a number of clinical trials, ranging from the occurrence of any BVAS item to the presence of at least 3 BVAS items (8) (9) (10) .
Our prespecified definition of "nonsevere" relapse attempts to account for differences in previously used terminology by defining such relapses generally as those with the occurrence of any new disease activity, a BVAS/WG of #3, and no major BVAS/WG items. We propose that nonsevere relapses be defined in future trials as any new disease activity that does not include a major BVAS/WG item. A standard definition of nonsevere flare would facilitate understanding of the clinical course and treatment response in this important patient subgroup. Whether a strict BVAS/WG of #3 should also be added to the definition to increase standardization further is uncertain, as some patients with a higher BVAS/WG may be considered by some experts to have nonsevere disease, as was the case for 3 patients in this study. It should be noted that disease manifestations that qualify for a "nonsevere" designation may have a profound impact on patients' prognosis and quality of life. For example, orbital pseudotumors and subglottic stenoses are features of "limited" or "localized" disease, yet they often lead to irreversible damage and substantial morbidity.
The high rate of second relapses observed in this subgroup of patients suggests a need for a treatment paradigm different from that used in the RAVE trial. Although prednisone was effective in reinducing remission in 80% of cases, the majority of patients treated in this manner did not sustain remission after prednisone had been tapered to a lower dose. In clinical practice, an addition or increase in the dose of AZA or MTX has been the standard of care for such disease relapses. B cell depletion may also be a viable approach in such patients (20, 21) . The recently reported trial of RTX versus AZA for maintenance in AAV (MAINRITSAN) demonstrated that RTX in combination with glucocorticoids was superior to AZA for prevention of disease relapses, suggesting that alternative regimens for maintenance of disease remission should be considered in AAV (21) . The optimal method for remission induction and maintenance in this setting needs to be evaluated further in clinical trials.
Time to second relapse was shorter in RTXtreated patients than in CYC/AZA-treated patients (4.7 months versus 13.7 months; P , 0.01). A possible explanation is that patients who were randomly assigned to receive RTX received placebo rather than AZA after achieving remission. Only 4 patients in the RTX-treated group had undetectable B cells at relapse, suggesting that the major effects of RTX had waned by the time of disease relapse. Despite this treatment difference, neither the rates of subsequent relapses nor patients' ability to achieve or maintain remission after a first nonsevere relapse differed between the CYC/AZA-treated and RTX-treated groups.
Our results suggest that AZA may prolong time to relapse in patients who have had a previous relapse, but the efficacy of AZA in preventing disease relapses altogether, particularly when glucocorticoids are withdrawn, has not been confirmed. Previous randomized, controlled studies of AZA for remission maintenance enrolled only patients with newly diagnosed disease (5,10) or maintained low-dose glucocorticoids for at least 18-24 months (5, 10, 21) . A recent retrospective series demonstrated that longer duration of AZA or MTX therapy reduced the rate of relapse (7) . However, that study examined only newly diagnosed patients whose disease had remained in remission for at least 18 months (7). Thus, previous trials have not addressed the specific patient subgroup described in the present study. In addition, the MAINRITSAN study demonstrated that despite concomitant glucocorticoid therapy for at least 18 months, 29% of patients treated with AZA experienced a severe relapse within 28 months, further calling into question the efficacy of AZA for maintaining disease remission (21) .
The use of low-dose glucocorticoids for remission maintenance remains a subject of controversy (22, 23) . It is notable that the median prednisone dosage among patients in this study who had a second disease relapse while receiving glucocorticoids was 7.5 mg/day. These data support the concept that many disease relapses occur in AAV despite continuous prednisone doses higher than those regarded generally as "low dose." Although the followup period in this study was likely too short to detect differences in treatment-related adverse events or damage, a recent study in patients with rheumatoid arthritis demonstrated that treatment with $8 mg/day prednisone was associated with an increase in death from any cause in a dose-dependent manner, suggesting that there may be substantial long-term effects of prolonged glucocorticoid use in doses required to maintain disease stability in GPA (24) . The currently ongoing "The Assessment of Prednisone In Remission" study may add to our understanding of the utility of low-dose prednisone in maintaining disease remission in AAV (25) .
Our study has several limitations. The starting prednisone dose for the treatment of nonsevere relapses was not standardized. However, the protocol permitted the investigator to select the appropriate starting dose based on clinical judgment, which accurately reflects the approach used in clinical practice. Moreover, the starting dose did not appear to affect the likelihood of achieving remission or experiencing a second relapse. The majority of patients in this study were PR3-ANCA positive, a population that is known to be at higher risk of relapse (9, 10, (26) (27) (28) . Therefore, the generalizability of our findings to MPO-ANCA-positive patients is not certain. Our study also has several strengths, including the protocolized study design, collection of data within the confines of a label-enabling clinical trial with rigorous data monitoring and regulatory agency oversight, and close patient followup throughout the study.
In conclusion, treatment of nonsevere relapses in AAV with a temporary increase in the glucocorticoid dose restores disease remission in most patients, but recurrent relapses within a relatively short time period remain common. Alternative approaches to the treatment of nonsevere relapses must be considered, including continuing glucocorticoids indefinitely or the use of B cell depletion in some patients.
